| The following company is how I'm playing this evolving issue for lowering the price for drugs. The company is Coherus Biosciences(CHRS) domiciled in Redwood City, California. The company issued their IPO back in November, 2014, at the price of $13.50 per share. Coherus is a pure play in the emerging biosimilar market for drugs. With Novartis getting FDA approval this week, for the first biosimilar product in the US, this in my opinion opens the door for other companies who have strong analytic skills and management. Coherus has three drugs in development with one in final Phase III testing that should allow them to file their BLA later this year. They also have partnership deals with Baxter and Daiichi-Sanyo. Since going public in November the stock is up more than 65%, but if they get approval of their lead candidate(Humira) the price of the stock at this level would be a bargain. |
